Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Gait Speed in Semaglutide-Inclusive Care
A 22-person observational study found faster gait after multidisciplinary obesity care but cannot isolate a semaglutide effect.
SURPASS-CVOT Heart Failure Analysis
An exploratory SURPASS-CVOT analysis compared tirzepatide and dulaglutide outcomes by prior heart-failure history.
Adolescent GLP-1 Review: Evidence Gaps
A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.
AGGF1 and the diabetic kidney barrier
A 2026 laboratory study links AGGF1 with glomerular barrier leakage and semaglutide-related junction changes in diabetic mice.
GLP-1s in Foot and Ankle Surgery
A 2026 review found neutral or potentially better outcomes with perioperative GLP-1 use, but all three comparative studies were retrospective.
Obesity and Facial Plastic Surgery
A 2026 review links obesity, weight loss and injectable drugs to facial-surgery questions but reports no direct patient outcomes.
PYY(3-36) and semaglutide in rat MASLD
A 48-rat MASLD study found stronger liver and mitochondrial changes with PYY(3-36) plus semaglutide, but it provides no human efficacy evidence.
Retatrutide and cognition in diabetic rats
A rat study linked retatrutide with better maze performance and lower brain inflammation, but it provides no evidence of cognitive benefit in people.
SUSTAIN OPTIMIZE: Semaglutide Trial
A 573-person trial found lower HbA1c and weight with semaglutide plus reduced insulin than with further insulin glargine titration.
Tirzepatide 2.5 vs 5 mg: Japanese cohort
A non-randomized Japanese cohort reported similar six-month weight loss with 2.5 mg and 5 mg tirzepatide, without proving dose equivalence.
Tirzepatide in adolescent MASLD
A two-patient case series links tirzepatide with lower weight, liver enzymes and imaging markers in 18-year-olds with MASLD.
Tirzepatide in Heart Failure: Review
A 2026 meta-analysis links tirzepatide to lower cardiorenal biomarkers, while functional and kidney findings remain based on single trials.